Skip to content

Study · Animal study (in vivo) · mouse · 2017

6 results

Teriparatide Treatment Improves Bone Defect Healing Via Anabolic Effects on New Bone Formation and Non-Anabolic Effects on Inhibition of Mast Cells in a Murine Cranial Window Model.

Zhang L, Wang T, Chang M, Kaiser C, Kim JD, Wu T, Cao X, Zhang X, Schwarz EM

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research19 Jul 2017Cited by 29 (Europe PMC)

PMID28556967 (opens in a new tab)PMCIDPMC5555820 (opens in a new tab)DOI10.1002/jbmr.3178 (opens in a new tab)PepBankPUB-28556967
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice with calvarial defects, rPTH increased defect window closure more than sodium cromolyn, which exceeded placebo.

    In plain wordsIn mice with skull defects, teriparatide increased defect closure more than sodium cromolyn, which exceeded placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseDefect window closure versus placebo
    Study

    mousen: not reported in source

    Critical calvaria defect
    Comparator
    Saline placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg/kg/2 daysAs given in this study (mouse).

    Source sentences

    Summary
    μCT demonstrated that SC significantly increased defect window closure and new bone volume versus placebo (p < 0.05), although these effects were not as great as rPTH.
    2 context sentences
    Summary · context
    To better understand these non-anabolic effects, we interrogated osteogenesis, vasculogenesis, and mast cell accumulation in mice randomized to placebo (saline), rPTH (20 μg/kg/2 days), or the mast cell inhibitor sodium cromolyn (SC)
    Summary · context
    (24 μg/kg/ 2days), via longitudinal micro-computed tomography (μCT) and multiphoton laser scanning microscopy (MPLSM), in a critical calvaria defect model.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice with calvarial defects, rPTH increased defect window closure more than sodium cromolyn.

    In plain wordsIn mice with skull defects, teriparatide increased defect closure more than sodium cromolyn.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseDefect window closure versus sodium cromolyn
    Study

    mousen: not reported in source

    Critical calvaria defect
    Comparator
    Sodium cromolyn
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg/kg/2 daysAs given in this study (mouse).

    Source sentences

    Summary
    μCT demonstrated that SC significantly increased defect window closure and new bone volume versus placebo (p < 0.05), although these effects were not as great as rPTH.
    2 context sentences
    Summary · context
    To better understand these non-anabolic effects, we interrogated osteogenesis, vasculogenesis, and mast cell accumulation in mice randomized to placebo (saline), rPTH (20 μg/kg/2 days), or the mast cell inhibitor sodium cromolyn (SC)
    Summary · context
    (24 μg/kg/ 2days), via longitudinal micro-computed tomography (μCT) and multiphoton laser scanning microscopy (MPLSM), in a critical calvaria defect model.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mice with calvarial defects, rPTH increased new bone volume more than sodium cromolyn, which exceeded placebo.

    In plain wordsIn mice with skull defects, teriparatide increased new bone volume more than sodium cromolyn, which exceeded placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseNew bone volume versus placebo
    Study

    mousen: not reported in source

    Critical calvaria defect
    Comparator
    Saline placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg/kg/2 daysAs given in this study (mouse).

    Source sentences

    Summary
    μCT demonstrated that SC significantly increased defect window closure and new bone volume versus placebo (p < 0.05), although these effects were not as great as rPTH.
    2 context sentences
    Summary · context
    To better understand these non-anabolic effects, we interrogated osteogenesis, vasculogenesis, and mast cell accumulation in mice randomized to placebo (saline), rPTH (20 μg/kg/2 days), or the mast cell inhibitor sodium cromolyn (SC)
    Summary · context
    (24 μg/kg/ 2days), via longitudinal micro-computed tomography (μCT) and multiphoton laser scanning microscopy (MPLSM), in a critical calvaria defect model.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In mice with calvarial defects, rPTH increased new bone volume more than sodium cromolyn.

    In plain wordsIn mice with skull defects, teriparatide increased new bone volume more than sodium cromolyn.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseNew bone volume versus sodium cromolyn
    Study

    mousen: not reported in source

    Critical calvaria defect
    Comparator
    Sodium cromolyn
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg/kg/2 daysAs given in this study (mouse).

    Source sentences

    Summary
    μCT demonstrated that SC significantly increased defect window closure and new bone volume versus placebo (p < 0.05), although these effects were not as great as rPTH.
    2 context sentences
    Summary · context
    To better understand these non-anabolic effects, we interrogated osteogenesis, vasculogenesis, and mast cell accumulation in mice randomized to placebo (saline), rPTH (20 μg/kg/2 days), or the mast cell inhibitor sodium cromolyn (SC)
    Summary · context
    (24 μg/kg/ 2days), via longitudinal micro-computed tomography (μCT) and multiphoton laser scanning microscopy (MPLSM), in a critical calvaria defect model.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In mice with calvarial defects, rPTH inhibited arteriogenesis versus placebo, similarly to sodium cromolyn.

    In plain wordsIn mice with skull defects, teriparatide reduced artery formation versus placebo, similarly to sodium cromolyn.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseArteriogenesis
    Study

    mousen: not reported in source

    Critical calvaria defect
    Comparator
    Saline placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg/kg/2 daysAs given in this study (mouse).

    Source sentences

    Summary
    Interestingly, both rPTH and SC have similar inhibitory effects on arteriogenesis versus placebo (p < 0.05) without affecting total vascular volume.
    2 context sentences
    Summary · context
    To better understand these non-anabolic effects, we interrogated osteogenesis, vasculogenesis, and mast cell accumulation in mice randomized to placebo (saline), rPTH (20 μg/kg/2 days), or the mast cell inhibitor sodium cromolyn (SC)
    Summary · context
    (24 μg/kg/ 2days), via longitudinal micro-computed tomography (μCT) and multiphoton laser scanning microscopy (MPLSM), in a critical calvaria defect model.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In mice with calvarial defects, rPTH did not affect total vascular volume versus placebo.

    In plain wordsIn mice with skull defects, teriparatide did not change total blood vessel volume versus placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeTotal vascular volume
    Study

    mousen: not reported in source

    Critical calvaria defect
    Comparator
    Saline placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg/kg/2 daysAs given in this study (mouse).

    Source sentences

    Summary
    Interestingly, both rPTH and SC have similar inhibitory effects on arteriogenesis versus placebo (p < 0.05) without affecting total vascular volume.
    2 context sentences
    Summary · context
    To better understand these non-anabolic effects, we interrogated osteogenesis, vasculogenesis, and mast cell accumulation in mice randomized to placebo (saline), rPTH (20 μg/kg/2 days), or the mast cell inhibitor sodium cromolyn (SC)
    Summary · context
    (24 μg/kg/ 2days), via longitudinal micro-computed tomography (μCT) and multiphoton laser scanning microscopy (MPLSM), in a critical calvaria defect model.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.